A 4 Week Study of Elidel for the Treatment of Seborrheic Dermatitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is an exploratory study to determine effectiveness of Elidel for the treatment of seborrheic dermatitis
Condition or disease
This is a 4 week study for patients 18 and olderto compare the efficacy and safety of pimecrolimus cream 1% twice daily and ketaconazole cream 2 % twice daily for the treatment of seborrheic dermatitis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Must be 18 or older and sign written informed consent.
Must be wiling and able to comply with protocol.
Must have active seborrheic dermatitis of the face.
No history of overt bacterial, viral or fungal infection of the head/neck.
No history or presence of compromising dermatosis elsewhere on the skin
No Parkinson's disease, HIV, infections or disorders of the central nervous system